Last update 01 Jul 2024

Niclosamide

Last update 01 Jul 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

FW-CD, FW-COV, FW-ICI-AC

+ [24]

Target

AR-v7

Mechanism

AR-v7 inhibitors(androgen receptor splice variant 7 inhibitors), Mitochondrial oxidative phosphorylation uncouplers

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesDigestive System Disorders+ [1]

Active Indication

COVID-19ProctocolitisUlcerative proctitis+ [3]

Inactive Indication

AscariasisDiabetic Nephropathies

Originator Organization

Bayer Pharmaceuticals Corp.

Active Organization

Entero Therapeutics, Inc.

First Wave Bio, Inc.

TFF Pharmaceuticals, Inc.

+ [4]

Inactive Organization

Bayer AG

Daewoong Pharmaceutical Co., Ltd.

Tanta University

+ [1]

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Structure

Molecular FormulaC13H10Cl2N2O5

InChIKeyZBXRPLQCPHTHLM-UHFFFAOYSA-N

CAS Registry73360-56-2

Clinical Trials associated with Niclosamide

NCT05188170 / RecruitingPhase 1IIT

Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

Start Date21 Nov 2022

Sponsor / Collaborator

Stanford University

KCT0007307 / CompletedPhase 2

A randomized, double-blind, placebo-controlled design phase 2 clinical trial to comparatively evaluate the efficacy and safety of CP-COV03 in patients with mild or moderate COVID-19

Start Date11 May 2022

Sponsor / Collaborator

HYUNDAI BIOSCIENCE Co., Ltd.

NCT05226533 / TerminatedPhase 2

A Phase 2, Double Blind, Randomized, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of DWRX2003 in Combination With Remdesivir Following Intramuscular Administration in Moderate-Severe COVID-19 Patients

Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.

Start Date31 Mar 2022

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Niclosamide

100 Translational Medicine associated with Niclosamide

100 Patents (Medical) associated with Niclosamide

1,106

Literatures (Medical) associated with Niclosamide

05 Jul 2106·Oncotarget

Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling

Article

Author: Zhang, Junxiang ; Zhang, Yaping ; Yin, Lina ; Zhang, Xuxia ; Wang, Jing ; Gao, Yun ; Chen, Honghong ; Ding, Defang

Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC. We herein reported that ionizing radiation (IR) induced Wnt3a, LRP6 and β-catenin expression and consequently activated Wnt/β-catenin signaling in TNBC MDA-MB-231, MDA-MB-468 and Hs578T cells. Moreover, depletion of β-catenin by shRNA sensitized TNBC cells to IR, whereas treatment of Wnt3a protein or overexpression of β-catenin resulted in radioresistance of TNBC cells. Niclosamide, a potent inhibitor of Wnt/β-catenin signaling, not only inhibited constitutive Wnt/β-catenin signaling, but also blocked IR-induced Wnt/β-catenin signaling in TNBC cells. In addition, niclosamide sensitized TNBC cells to IR, prevented Wnt3a-induced radioresistance, and overcame β-catenin-induced radioresistance in TNBC cells. Importantly, animals treated with the combination of niclosamide and γ-ray local tumor irradiation had significant inhibition of MDA-MB-231 tumor growth compared with treated with local tumor irradiation alone. These findings indicate that Wnt/β-catenin signaling pathway plays an important role in the development of radioresistance of TNBC cells, and that niclosamide had significant radiosensitizing effects by inhibiting Wnt/β-catenin signaling in TNBC cells. Our study also provides rationale for further preclinical and clinical evaluation of niclosamide in TNBC management.

01 Feb 2024·Toxicology and applied pharmacology

Chemical mixture that targets the epidermal growth factor pathway impairs human trophoblast cell functions

Article

Author: Ticiani, Elvis ; Waye, Anita A ; Veiga-Lopez, Almudena

Pregnant women are exposed to complex chemical mixtures, many of which reach the placenta. Some of these chemicals interfere with epidermal growth factor receptor (EGFR) activation, a receptor tyrosine kinase that modulates several placenta cell functions. We hypothesized that a mixture of chemicals (Chem-Mix) known to reduce EGFR activation (polychlorinated biphenyl (PCB)-126, PCB-153, atrazine, trans-nonachlor, niclosamide, and bisphenol S) would interfere with EGFR-mediated trophoblast cell functions. To test this, we determined the chemicals' EGFR binding ability, EGFR and downstream effectors activation, and trophoblast functions (proliferation, invasion, and endovascular differentiation) known to be regulated by EGFR in extravillous trophoblasts (EVTs). The Chem-Mix competed with EGF for EGFR binding, however only PCB-153, niclosamide, trans-nonachlor, and BPS competed for binding as single chemicals. The effects of the Chem-Mix on EGFR phosphorylation were tested by exposing the placental EVT cell line, HTR-8/SVneo to control (0.1% DMSO), Chem-Mix (1, 10, or 100 ng/ml), EGF (30 ng/ml), or Chem-Mix + EGF. The Chem-Mix - but not the individual chemicals - reduced EGF-mediated EGFR phosphorylation in a dose dependent manner, while no effect was observed in its downstream effectors (AKT and STAT3). None of the individual chemicals affected EVT cell invasion, but the Chem-Mix reduced EVT cell invasion independent of EGF. In support of previous studies that have explored chemicals targeting a specific pathway (estrogen/androgen receptor), current findings indicate that exposure to a chemical mixture that targets the EGFR pathway can result in a greater impact compared to individual chemicals in the context of placental cell functions.

01 Feb 2024·The Science of the total environment

Effects of environmentally relevant concentrations of niclosamide on lipid metabolism and steroid hormone synthesis in adult female zebrafish

Article

Author: Zhou, Bingsheng ; Yang, Lihua ; Han, Jian ; Chen, Xianglin ; Zhu, Biran ; Yang, Shangyue ; Li, Ruiwen ; Zhang, Mengyuan ; Hua, Jianghuan ; Zheng, Na

Niclosamide (NIC) is a commonly used molluscicide that reportedly disrupts the endocrine system and may lead to lipid metabolism disorders. However, few studies have investigated the mechanism by which NIC affects the endocrine system from the perspective of lipid metabolism. Adult female zebrafish were fed either a normal-fat diet (NFD) or a high-fat diet (HFD) and then exposed for 28 days to environmentally relevant concentrations of NIC. NIC accumulated most in the liver followed by the brain and then the gonads in both feeding conditions. Somatic index changes confirmed that HFD promotes fish growth, and NIC administration inhibits it. Lipid metabolites were decreased by NIC, as were levels of pregnenolone, androstenedione, estrogen, testosterone, and estradiol, suggesting that NIC impacted steroidogenesis. In addition, gene transcription changes related to the hypothalamic-pituitary-gonad-liver (HPGL) axis and altered ovarian histology strongly suggest that environmental relevant concentrations of NIC exposure may disrupt endocrine function. These findings highlighted that NIC exposure at environmentally relevant concentrations elicited endocrine-disruption effects may through impairing of steroid hormone synthesis.

135

News (Medical) associated with Niclosamide

27 Jun 2024

·www.sciencedaily.com

Intriguing new tool for tendon healing: nanoparticles for precision drug delivery

Harnessing nanoparticles to deliver drugs precisely to a surgically repaired tendon is a promising new approach that reduced scar tissue formation and improved mechanical function. Harnessing nanoparticles to deliver drugs precisely to a surgically repaired tendon is a promising new approach that reduced scar tissue formation and improved mechanical function in a study appearing in Science Advances. Researchers' success in pinpointing a drug therapy inside the body, at the cellular level, proved to be a highly efficient delivery method that could be used to treat other injuries. Whether it's a season-ending Achilles rupture by pro footballer Aaron Rodgers or an everyday workplace accident, tendon injuries are common and can be life-changing. They require 300,000 surgeries per year and often result in lost work time and permanent impaired physical function. Typically, traumatic tendon injuries are surgically repaired with sutures, but optimal healing is often impaired by the tendon's propensity to heal with scar tissue that restricts tendon movement and function. Researchers at the University of Rochester and University of Oregon combined their expertise in tendon cell biology and drug delivery systems to find a better way to deliver therapies that can reduce scar tissue and facilitate improved healing. "There are very few effective drug regimens to assist the tendon healing process, despite the high number of these injuries and the poor outcomes that often result," said Alayna Loiselle, PhD, associate professor at the University of Rochester's Center for Musculoskeletal Research. "Systemic drug treatments delivered orally or via injection show poor tendon homing; in some cases, less than 1 percent of a systemically delivered medication reaches the healing tendon. Local administration of drugs directly to the tendon has disadvantages as well, including potential tissue damage from the injection and poor control over drug concentrations at the point of injury." "We want to pivot from using suturing alone to incorporating therapeutics," said Emmanuela Adjei-Sowah, a Biomedical Engineering PhD student at the University of Rochester, who has spent the past several years working with co-authors Loiselle, Danielle S.W. Benoit, PhD, and others to develop the nanoparticle delivery system to improve healing in tendon injuries. "Advances in multiomics and drug delivery using nanoparticles open up new possibilities in treatment." The challenge for researchers was to identify which substances could assist tendon healing. Molecular 'map' of healing process charts a new therapeutic path "The fundamental cellular and molecular mechanisms that drive scar-mediated tendon healing are really only just beginning to be well-defined," Loiselle said. "Our prior work used spatial transcriptomic profiling to define a molecular map of the healing tendon. In subsequent analysis of this data, we found that the area right at the injury site had high levels of Acp5 gene expression, which was both surprising and exciting." The Acp5 gene produces a protein called Tartrate Resistant Acid Phosphatase (TRAP); both are known to occur as injured bones recover and rebuild. High TRAP activity within the healing tendon allowed researchers to employ a peptide that binds with TRAP to deliver medication directly to the healing tendon site. "While Benoit's lab has previously used TRAP-binding peptide nanoparticles (TBP-NP) for targeted drug delivery to bone, high TRAP activity in the healing tendon opened up an entirely new research direction," Loiselle said. Prior to initiating studies with therapeutic agents, the team completed a series of dose and timing studies, using a mouse model of complete transection and surgical repair of the flexor tendon, to define the window in which their drug delivery system could most effectively target the healing tendon. "Defining an optimal treatment window is critical to successfully developing an innovative and effective drug delivery system that improves tendon healing by encouraging a more regenerative, rather than fibrotic, healing cascade," said Benoit, the Lorry Lokey Department Chair and Professor in the Department of Bioengineering at the University of Oregon. "In addition, by defining the optimal therapeutic window for this drug delivery system, we can mitigate the unwanted side effects that typically accompany the high doses or multiple doses required to achieve sufficient drug accumulation in the tissue." As a therapeutic, the team chose Niclosamide, which inhibits S100a4, a protein that Loiselle's lab already identified as contributing to scar formation. Previous work from Loiselle's lab demonstrated that genetic knockdown of S100a4 improved mechanical and functional outcomes in this mouse tendon healing model. S100a4 has been implicated in scar formation in many tissues, including the liver, heart, lung, and oral submucosa; Loiselle's discovery that it complicates tendon healing gave them a therapeutic target for this study, where they used their TRAP-binding peptide nanoparticle drug delivery system to precisely affect the injured tendon. As a comparison, they delivered Niclosamide systemically; it did slightly reduce the amount of S100a4 in the healing tendon but it had no beneficial impact on the healing process. In contrast, delivery of the same dose of Niclosamide using the nanoparticle system resulted in robust inhibition of S100a4 mRNA and protein levels in the healing tendon. This targeted drug delivery method also significantly benefited the tendon healing process. TBP-NP delivery of Niclosamide improved both functional range of motion recovery and increased the mechanical integrity of the healing tendon across both short- and longer-term timepoints. Importantly, these sustained effects occurred with just a single treatment. Researchers will continue their work to define how broadly the system can be used for other tendon injuries and disease, as well as other types of tissue injury that result in scar formation. "The beauty of this system is that it can be loaded with different kinds of drugs to target different molecular processes or pathways," said Adjei-Sowah.

26 Jun 2024

·www.prnewswire.com

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted in Brazil. SEOUL, South Korea, June 25, 2024 /PRNewswire/ -- Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for mosquito-borne viral infections, including dengue fever,' using niclosamide as the main ingredient. This treatment, which contains niclosamide as the main active pharmaceutical ingredient, can maintain a blood niclosamide concentration (IC50) to inhibit the proliferation of viruses such as the four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever, by 50%. To effectively treat dengue fever, the antiviral must be administered early, before the viral load increases significantly. For early administration, the treatment must be effective not only against dengue fever but also against other mosquito-borne viral diseases with similar symptoms, such as Zika, Chikungunya, and Yellow Fever. Leveraging its patented technology, Hyundai Bioscience has enhanced the bioavailability of niclosamide, enabling it to treat arbovirus infections caused by Zika, Chikungunya, and Yellow Fever viruses in addition to dengue fever. Recently, the company has succeeded in developing a "niclosamide-based multi-treatment for mosquito-borne viral infections" that can maintain an IC50 in the blood to inhibit the replication of these viruses. Currently, there is no treatment for dengue fever. The dengue virus has four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), each with different IC50 values. The IC50 values for Zika, Chikungunya, and Yellow Fever viruses, which are also mosquito-borne, vary as well. Hyundai Bioscience's multi-treatment drug candidate is the world's first to maintain niclosamide's blood concentration above the IC50 value of all four serotypes of dengue virus as well as Zika, Chikungunya, and Yellow Fever viruses. Hyundai Bioscience has formulated the multi-treatment antiviral into a tablet form to facilitate mass production and to make it convenient for transportation and storage. Hyundai Bioscience has decided to conduct the dengue fever basket clinical trial in Brazil, the country most affected by dengue fever. Hyundai Bioscience USA will soon select a Contract Research Organization (CRO). The dengue fever clinical trial, to be conducted by Hyundai Bioscience USA in Brazil, will use a basket clinical trial approach, differing from traditional clinical trial methods. This involves early administration of the multi-target antiviral to patients infected with mosquito-borne viruses, including the four serotypes of dengue virus, Zika, and Chikungunya, followed by evaluating the clinical efficacy in patients with confirmed dengue virus. Kim Kyung-il, CEO of Hyundai Bioscience USA, stated, "With the development of a multi-treatment drug candidate capable of simultaneously treating various mosquito-borne viral infections such as dengue fever, we plan to conduct the basket clinical trial in Brazil as soon as possible. Through expedited regulatory processes in Brazil, we aim to supply the treatment at an affordable price to patients suffering from dengue fever worldwide." About Hyundai Bioscience Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). SOURCE Hyundai Bioscience

Clinical Study

26 Jun 2024

·www.biospace.com

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities. “We are pleased to announce this engagement with Outcome Capital, which is a well-recognized investment bank specializing in corporate advisory services to the life sciences industry,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. “Today’s announcement reflects the significant innovation and commercial potential of our two lead clinical assets, TFF VORI and TFF TAC, and we welcome the opportunity to work with Outcome Capital in evaluating select partnering or licensing opportunities that can bring significant value to our shareholders.” “In recent months, TFF Pharmaceuticals has made extraordinary progress in demonstrating how its leading formulation technology can be applied to generate innovative clinical-stage products with the potential to improve upon the current standard of care,” said Oded Ben-Joseph, Ph.D., MBA, Managing Partner of Outcome Capital. “We look forward to identifying and evaluating opportunities to realize the full potential value of TFF Pharmaceutical’s exciting Phase 2 assets.” About TFF TAC TFF TAC is an inhaled dry powder formulation of tacrolimus, a potent immunosuppressive drug. Oral tacrolimus is currently the first line calcineurin inhibitor used for prevention of rejection after solid organ transplantation but it is associated with many toxicities such as kidney toxicity, particularly when high doses are needed as is the case after lung transplantation TFF TAC delivers tacrolimus directly to the lung to yield improved lung immunosuppression at lower doses and systemic exposures compared to oral tacrolimus to improve efficacy and decrease systemic toxicities such as kidney toxicity. TFF TAC is delivered via an easy-to-use dry powder inhaler. The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity. Part A of the trial is a 12-week treatment period, and Part B is an optional safety extension period. Trial endpoints include safety and tolerability including kidney function, acute allograft rejection and pharmacokinetics. ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGY TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by TFF can deliver as much as 75% of the dose to the deep lung. TFF does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. ABOUT TFF PHARMACEUTICALS TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation or for topical delivery to the eyes, nose and skin. SAFE HARBOR This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the innovation and commercial potential of the Company’s TFF VORI and TFF TAC product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including (i) the risk that the Company may not realize the innovation and commercial potential of TFF VORI and TFF TAC through its collaboration with Outcome Capital or otherwise, (ii) success in early phases of pre-clinical and clinical trials do not ensure later clinical trials will be successful; (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. InvestorRelationsContact: Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577 cdavis@lifesciadvisors.com

Phase 2

100 Deals associated with Niclosamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00436	Niclosamide	P02DA01	DB06803

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ascariasis	US	Bayer Pharmaceuticals Corp.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	US	NeuroBo Pharmaceuticals, Inc.	07 Oct 2020
Diabetic Nephropathies	Phase 3	EG	Tanta University	01 Feb 2020
Gastrointestinal infection	Phase 2	US	Entero Therapeutics, Inc.	30 Apr 2021
Gastrointestinal infection	Phase 2	IN	Entero Therapeutics, Inc.	30 Apr 2021
Gastrointestinal infection	Phase 2	UA	Entero Therapeutics, Inc.	30 Apr 2021
Proctocolitis	Phase 2	IT	Entero Therapeutics, Inc.	15 May 2018
Ulcerative proctitis	Phase 2	IT	Entero Therapeutics, Inc.	15 May 2018
Crohn Disease	Phase 1	-	First Wave Bio, Inc.	-
Diarrhea	Preclinical	US	First Wave Bio, Inc.	15 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04317430 (Literature) Manual	Phase 3	Diabetic Nephropathies	60	niclosamide+ramipril	ipgxhfowfg(lapqlkjydr) = tpzyfsjsmf xhdtmldsek (tuuhxftvxn, -30to-18.3) View more	Positive	16 Feb 2023
NCT04317430 (Literature) Manual	Phase 3	Diabetic Nephropathies	60	ramipril	ipgxhfowfg(lapqlkjydr) = vtiinrlhld xhdtmldsek (tuuhxftvxn, 4to18.2) View more	Positive	16 Feb 2023
NCT04399356 (Pubmed) Manual	Phase 2	COVID-19	73	Niclosamide	iwjivayjwg(ysfeudbudp) = jnfvhjyouv xyyvczzalr (huxvdnndow, 50.74 - 81.81) View more	Negative	01 Feb 2022
NCT04399356 (Pubmed) Manual	Phase 2	COVID-19	73	Placebo	iwjivayjwg(ysfeudbudp) = jzzhmiircf xyyvczzalr (huxvdnndow, 40.27 - 72.73) View more	Negative	01 Feb 2022
NCT02807805 (ASCO2018)	Phase 2	Castration-Resistant Prostatic Cancer	6	Niclosamide/PDMX1001 + Abiraterone + Prednisone	gnmsktlfbx(afchjhisdz) = two with partial PSA response (≥50% decrease) epnonntdxl (rvkjjpzmjv ) View more	Positive	01 Jun 2018
ASN2016	Not Applicable	Reperfusion Injury	-	Niclosamide	qgtdqqqidb(okyjvhjovx) = I/R-induced fatty acid deposition in tubular epithelium was almost diminished in niclosamide-treated mice nccpuetszt (zztoxbvbub ) View more	Positive	15 Nov 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis